Home › Interstitial Lung Diseases › NCT01280994

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

Inclusion Criteria for Healthy Control Subjects

1. Subject has no diagnosed pulmonary conditions
2. Subject has not smoked in the previous 5 years.
3. Smoking history, if any, is less than or equal to 5 pack-years.

Inclusion Criteria for Subjects with lung disease

1. Subject has a diagnosis of pulmonary dysfunction made by a physician
2. No acute worsening of pulmonary function in the past 30 days

Exclusion Criteria:

1. Subject is less than 18 years old
2. MRI is contraindicated based on responses to MRI screening questionaire
3. Subject is pregnant or lactating
4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI
5. Subject has received an investigational medicinal product (not including 129Xe) within 30 days of MRI
6. Subject has any form of known cardiac arrhythmia
7. Subject does not fit into 129Xe vest coil used for MRI
8. Subject cannot hold his/her breath for 15 seconds
9. Subject deemed unlikely to be able to comply with instructions during imaging

About the study

The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.

What is being tested

• Hyperpolarized 129Xenon Gas (drug)

Sponsor: Bastiaan Driehuys · Participants: 445 · Started: 2011-01

Contact the study team

• Jennifer Korzekwinski · Phone: 919-681-7362
• Cody Blanton · Phone: 919-668-7575

Official record on ClinicalTrials.gov — NCT01280994

Locations in the U.S.

Conditions

• Interstitial Lung Diseases
• Lung Diseases

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.